Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea for NVAMD after bevacizumab or ranibizumab failure
NCT01918878Phase 4Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- Oct 2013
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Hadassah Medical Organization. Status: unknown.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01918878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01918878.